AU2003263978A1 - 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections - Google Patents

2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections

Info

Publication number
AU2003263978A1
AU2003263978A1 AU2003263978A AU2003263978A AU2003263978A1 AU 2003263978 A1 AU2003263978 A1 AU 2003263978A1 AU 2003263978 A AU2003263978 A AU 2003263978A AU 2003263978 A AU2003263978 A AU 2003263978A AU 2003263978 A1 AU2003263978 A1 AU 2003263978A1
Authority
AU
Australia
Prior art keywords
flavivitridae
infections
prevention
treatment
dideoxynucleoside analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003263978A
Other versions
AU2003263978A8 (en
Inventor
Raymond F. Schinazi
Junxing Shi
Robert Striker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmasset Ltd
Emory University
Leland Stanford Junior University
Original Assignee
Pharmasset Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Ltd filed Critical Pharmasset Ltd
Publication of AU2003263978A8 publication Critical patent/AU2003263978A8/en
Publication of AU2003263978A1 publication Critical patent/AU2003263978A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003263978A 2002-08-01 2003-08-01 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections Abandoned AU2003263978A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45371502P 2002-08-01 2002-08-01
US60/453,715 2002-08-01
PCT/US2003/024288 WO2004013298A2 (en) 2002-08-01 2003-08-01 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections

Publications (2)

Publication Number Publication Date
AU2003263978A8 AU2003263978A8 (en) 2004-02-23
AU2003263978A1 true AU2003263978A1 (en) 2004-02-23

Family

ID=31496097

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003263978A Abandoned AU2003263978A1 (en) 2002-08-01 2003-08-01 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections

Country Status (2)

Country Link
AU (1) AU2003263978A1 (en)
WO (1) WO2004013298A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060084845A (en) 2003-07-25 2006-07-25 이데닉스 (케이만) 리미티드 Purin nucleoside analogues for treating flaviviridae including hepatitis c
AU2006275413B2 (en) * 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CN101437534A (en) 2006-03-08 2009-05-20 半球生物制药公司 Broad spectrum immune and antiviral gene modulation by oral interferon
US8075877B2 (en) 2006-03-08 2011-12-13 Hemispherx Biopharma Broad spectrum immune and antiviral gene modulation by oral interferon
PL2794629T3 (en) * 2011-12-20 2018-02-28 Riboscience Llc 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
US11963972B2 (en) 2016-03-23 2024-04-23 Emory University Antiviral agents and nucleoside analogs for treatment of Zika virus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL364995A1 (en) * 2000-02-18 2004-12-27 Shire Biochem Inc. Method for the treatment or prevention of flavivirus

Also Published As

Publication number Publication date
WO2004013298A2 (en) 2004-02-12
AU2003263978A8 (en) 2004-02-23
WO2004013298A3 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
IL160187A0 (en) Aerosolized decongestants for the treatment of sinusitis
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
PL376454A1 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
AU2001272852A1 (en) Composition for the treatment of migraine
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
AU2001260834A1 (en) The treatment of herpes
AU2002236781A1 (en) Treatment for snoring
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
AU2003263978A1 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
AU2021601A (en) Composition for the treatment of dandruff
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
AU2003237088A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2001258675A1 (en) Treating infections
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003223098A1 (en) Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone
AU1673200A (en) Medicaments for the treatment of lung infections
AU2003285261A1 (en) Compositions for the treatment of mycobacterial infections
AU2003216904A1 (en) Aqueous formulations of (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase